15,488 Shares in Voyager Therapeutics, Inc. $VYGR Acquired by R Squared Ltd

R Squared Ltd acquired a new position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) during the second quarter, HoldingsChannel.com reports. The fund acquired 15,488 shares of the company’s stock, valued at approximately $48,000.

Several other large investors have also added to or reduced their stakes in the business. Privium Fund Management B.V. increased its holdings in Voyager Therapeutics by 16.6% in the second quarter. Privium Fund Management B.V. now owns 25,241 shares of the company’s stock worth $79,000 after purchasing an additional 3,596 shares in the last quarter. American Century Companies Inc. increased its holdings in Voyager Therapeutics by 7.2% in the first quarter. American Century Companies Inc. now owns 131,521 shares of the company’s stock worth $445,000 after purchasing an additional 8,795 shares in the last quarter. CWM LLC increased its holdings in Voyager Therapeutics by 856.3% in the first quarter. CWM LLC now owns 10,471 shares of the company’s stock worth $35,000 after purchasing an additional 9,376 shares in the last quarter. Patriot Financial Group Insurance Agency LLC increased its holdings in Voyager Therapeutics by 10.0% in the second quarter. Patriot Financial Group Insurance Agency LLC now owns 121,098 shares of the company’s stock worth $377,000 after purchasing an additional 11,000 shares in the last quarter. Finally, Vestal Point Capital LP increased its holdings in Voyager Therapeutics by 1.6% in the first quarter. Vestal Point Capital LP now owns 1,249,418 shares of the company’s stock worth $4,223,000 after purchasing an additional 19,418 shares in the last quarter. Institutional investors and hedge funds own 48.03% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on VYGR shares. Weiss Ratings reiterated a “sell (d)” rating on shares of Voyager Therapeutics in a report on Friday. Wedbush lowered their target price on Voyager Therapeutics from $9.00 to $8.00 and set an “outperform” rating for the company in a report on Thursday, August 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research note on Monday, September 15th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $12.96.

Voyager Therapeutics Stock Performance

Shares of Voyager Therapeutics stock opened at $4.65 on Monday. Voyager Therapeutics, Inc. has a 52 week low of $2.64 and a 52 week high of $7.44. The stock has a 50 day moving average price of $4.30 and a two-hundred day moving average price of $3.62. The stock has a market capitalization of $257.94 million, a PE ratio of -2.51 and a beta of 0.95.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.09). Voyager Therapeutics had a negative net margin of 253.49% and a negative return on equity of 37.65%. The firm had revenue of $5.20 million during the quarter, compared to analyst estimates of $9.50 million. Research analysts forecast that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.

Insider Activity

In related news, CFO Nathan D. Jorgensen sold 7,666 shares of Voyager Therapeutics stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $4.78, for a total transaction of $36,643.48. Following the transaction, the chief financial officer owned 123,834 shares of the company’s stock, valued at $591,926.52. The trade was a 5.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 4.53% of the stock is currently owned by insiders.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.